ABPI And Top Pharma Execs Come Out Against Brexit
The Association of the British Pharmaceutical Industry has formally come out in support of the UK remaining part of the EU, saying that a vote to leave in next month's referendum would lead to delays in the availability of new drugs, have a detrimental effect on collaboration in European drug research, and discourage inward investment by international drug firms.
You may also be interested in...
Although the overwhelming voice of the pharma industry had been in favor of the UK remaining in the EU, business reaction to the Leave result was muted, and the general message was that there would be no noticeable impact on individual companies, at least for the time being.
With the UK about to go to the polls in a once-and-for-all decision on EU membership, the stakes for the life sciences sector are high. The effects of a Brexit would be far-reaching, not only for the industry but also for other key groups such as regulators, patients and researchers.
UK parliamentary committee warns that a vote to leave the EU would have negative effects on life science companies, such as impairing cross-border business and research collaboration, and calls on the government to prepare contingency measures should the June 23 referendum result in a Brexit.